Literature DB >> 19570492

Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis.

Jaspreet S Sandhu1.   

Abstract

Elevated serum prostate-specific antigen (PSA) in the setting of acute or chronic bacterial prostatitis is common. Serum PSA, however, is much more variable in the setting of chronic nonbacterial prostatitis. Because elevated serum PSA is associated with prostate cancer and is used in screening programs for prostate cancer, patients with benign causes for elevation of serum PSA present a challenge. This article reviews the management of patients with elevated serum PSA and a diagnosis of chronic nonbacterial prostatitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570492     DOI: 10.1007/s11934-009-0049-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  26 in total

1.  Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.

Authors:  J M Potts
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

3.  Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.

Authors:  Edward W J Rowe; Marc E Laniado; Marjorie M Walker; Patel Anup
Journal:  BJU Int       Date:  2006-05       Impact factor: 5.588

4.  Treatment of chronic prostatitis lowers serum prostate specific antigen.

Authors:  Caleb B Bozeman; Brett S Carver; James A Eastham; Dennis D Venable
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

6.  Precipitating antigens of the normal human prostate.

Authors:  R J Ablin; W A Soanes; P Bronson; E Witebsky
Journal:  J Reprod Fertil       Date:  1970-08

7.  Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer.

Authors:  K Okada; M Kojima; Y Naya; K Kamoi; K Yokoyama; T Takamatsu; T Miki
Journal:  Urology       Date:  2000-06       Impact factor: 2.649

8.  Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.

Authors:  James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.

Authors:  M Kuriyama; M C Wang; L D Papsidero; C S Killian; T Shimano; L Valenzuela; T Nishiura; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

Review 10.  Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.

Authors:  Ronald Lieberman
Journal:  Am J Ther       Date:  2004 Nov-Dec       Impact factor: 2.688

View more
  1 in total

1.  The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis.

Authors:  Li Gui-Zhong; Man Libo; Huang Guanglin; Wang Jianwei
Journal:  Int Urol Nephrol       Date:  2010-09-05       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.